Related Experiment Videos
Parvoviral vectors for the gene therapy of cancer
E Shaughnessy1, D Lu, S Chatterjee
1Department of General and the Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA.
Abstract:
Gene transfer vectors based on the replication-defective (adeno-associated virus, AAV) and autonomous parvoviruses are emerging as promising vehicles for gene therapeutic approaches for the treatment of cancer. AAV-based vectors are nonpathogenic, possess an extremely wide host and tissue range, stably integrate into cellular DNA, and transduce both proliferating and nonproliferating cells. Unlike AAV, autonomous parvoviruses such as the minute virus of mice (MVM) do not integrate. However, their tropism for transformed tissues and innate oncolytic properties may permit rapid in situ therapies. In this article, we briefly review basic parvovirus biology as it relates to vector development. In addition, parvoviral vectors are discussed within the context of applications for gene transfer approaches to cancer treatment including genetic marking studies, hematopoietic progenitor chemoprotection, interruption of oncogene expression, and modulation of antitumor immunity.
Insights
Parvovirus-based gene therapy vectors, including adeno-associated virus (AAV) and minute virus of mice (MVM), show promise for cancer treatment. Their unique properties offer potential for diverse therapeutic strategies against various cancers.
Area of Science:
- * Virology
- * Molecular Biology
- * Oncology
Background:
- * Gene transfer vectors are crucial for developing novel cancer therapies.
- * Adeno-associated virus (AAV) and autonomous parvoviruses are promising candidates for gene therapy.
- * Understanding parvovirus biology is key to optimizing vector development for cancer treatment.
Purpose of the Study:
- * To review parvovirus biology relevant to gene therapy vector development.
- * To discuss the application of parvoviral vectors in cancer treatment strategies.
- * To highlight the potential of AAV and MVM vectors in oncology.
Main Methods:
- * Review of existing literature on parvovirus biology and gene therapy.
- * Analysis of AAV and autonomous parvovirus characteristics for vector applications.
- * Discussion of specific cancer treatment approaches using parvoviral vectors.
Main Results:
- * Adeno-associated virus (AAV) vectors are nonpathogenic, integrate into DNA, and transduce various cell types.
- * Autonomous parvoviruses, like minute virus of mice (MVM), do not integrate but target transformed tissues and possess oncolytic potential.
- * Both AAV and MVM show potential for applications including genetic marking, chemoprotection, oncogene inhibition, and immunotherapy.
Conclusions:
- * Parvoviruses, particularly AAV and MVM, offer versatile platforms for gene therapy in cancer treatment.
- * Their distinct biological properties enable diverse therapeutic applications, from genetic modification to direct oncolysis.
- * Further development of parvoviral vectors holds significant promise for advancing cancer therapeutics.